FEEBLE REGULATORY AFFAIRS WEAKEN THE BACKBONE OF INDIAN DRUG INDUSTRIES
Abstract
India is emerging as a global outsourcing power house in almost all fields including Drugs and Pharmaceutical sector.
Now it becomes a hub to conduct clinical trials and contract researches. Pharmaceutical industry currently opts for
total quality management as primary criteria to prevent sub-standard products which do not fall under official
specifications. However, there are many areas where immediate regulatory measures are desired. Central Drugs
Standard Control organization (CDSCO) is the prime regulatory authority for the purpose of enforcement according
to the Drugs and Cosmetic Act 1940 and Rules 1945, with its amendments. There is no established system for
monitoring the Physician’s samples as it generally moves from medical representatives to patients via medical
professionals. Fixed dose combinations are approved by Drug Controller General of India without proper dose
schedule and indications. Metered dose inhaler is presented without dose counter, so that user cannot read how many
doses remain. The capacity of CDSCO/the licensing authority/ controlling authority at both national and state level
need to be matched with Pharmaceutical Industry in term of man power, infrastructure and training to provide safe
and effective drugs to the patients. In the present review, those areas have been highlighted along with some possible
solutions such as more stringency and uniformity in drug regulatory policies, use of software to identify duplicate and
misbranded medicines, speedy functioning of drug regulatory authorities etc.
Downloads
References
Companies in India, Contributions to Economics.
Heidelberg: Springer-Verlag Berlin; 2013.
2. Pai A, Sudhakar GK, Kamath V, Pai V. Role of short
term campaigns in boosting up sales, with special
emphasis on Indian pharmaceutical market. Int J
Pharm. 2014; 4(1):74-6.
3. Expert speak: How Indian pharma companies grow
their business. [Internet]. Business today;2014 [cited
2014 Oct 13]. Available from:
businesstoday.intoday.in/pharmaceutical-companiesindia
/202812.ht
4. Global pharma looks to India: Prospects for growth.
[Internet]. 2014 [cited 2014 Oct 13].
Available from:
https://www.pwc.in/assets/.../pharma/Global_Pharma
_looks_to_India.pdf.
5. Manual on foreign direct investment in India –
Policies and Procedures, Ministry of Commerce and
Industry, Govt. of India. [Internet]. India; 2003 May
[cited 2014 Oct 13]. Available from:
www. iaccindia.com/userfiles/files/FDI%20Manual%
20-%20Policy%20and%20Procedure. pdf.
6. Shah V. Evolution of Pharmaceutical Industry: A
global Indian & Gujarat perspective. J Pharm Sci
Bioscientific Research. 2012; 2(5):219-29.
7. India is a land of opportunities, invest in Indian
Pharmaceutical Industry. [Internet]. India; [date
unknown] [cited 2014 Oct 13]. Available from:
www. ansarilawin.com.
8. Mckinsey: India Pharma 2020 Propelling access and
acceptance, realising true potential. [Internet]. [Place
unknown]; [date unknown] [cited 2014 Oct
13].Available from: biospectrum.htp.
9. Annual report 2012.pdf. [Internet]. [Place unknown];
[date unknown] [cited 2014 Oct 13]. Available from:
www.pharmaceuticals.gov.in.
10. Pharma industries in India. [Internet]. CDSCO, India;
2014 [cited 2014 Oct 13]. Available from:
www.cdsco.nic.in
11. Pharmaceutical industry in India: from Wikipedia, the
free encyclopedia. [Internet]. Wikipedia, India; 2014
[cited 2014 Oct 13]. Available from:
en.wikipedia.org/wiki/pharmaceutical_industry_in
_india.
12. Indian Pharmaceutical industry: an overview.
[Internet]. shodhganga, India; 2014 [cited 2014 Oct
13]. Available from: shodhganga.inflibnet.ac.in
13. DCGI directs manufacturers of Nimesulide to add
“box warning”, Thrusday. 2012 April 19.
14. Withdraw multiple drugs sold under same name:
DCGI posted on 3:19 a.m. by deborahhelm.
15. Novartis drug scandal may taint Japaneese clinical
research. [Internet]. Tokyo; 2013 Oct [cited 2014 Oct
13]. Available from: drugs.com
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
